Deciding Between Quadruplet and Triplet Therapy in Transplant-Preferred NDMM: Key Considerations
Panelists discuss how the decision between quadruplet versus triplet therapy depends on multiple factors, including cytogenetic risk status, insurance coverage/drug access, patient fitness to tolerate additional toxicity, and the strength of evidence supporting improved outcomes with 4-drug combinations.
EP: 1.Current Strategies for Frontline Therapy in Transplant-Preferred NDMM
EP: 2.Brief Overview of PERSEUS, IsKia, and CASSIOPEIA Clinical Trials
EP: 3.Deciding Between Quadruplet and Triplet Therapy in Transplant-Preferred NDMM: Key Considerations
EP: 4.Insights of MAIA, BENEFIT, and IMROZ Trials on Frontline Treatment for Transplant Not-Preferred NDMM
EP: 5.Initial Impressions of the CEPHEUS Clinical Trial in Transplant Not-Preferred NDMM
EP: 6.Clinical Experience in CAR-T-Cell Therapy in Early Relapsed MM and Insights From the CARTITUDE-4 Trial
Video content above is prompted by the following:
What factors do you consider when choosing between quadruplet or triplet therapy in transplant-preferred newly diagnosed multiple myeloma (NDMM)?
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
